Drug-inducible gene therapy for glioblastoma shows promise in clinical trial

Written by Louis Gautier, Future Science Group

Veledimex – an oral activator of the human interleukin-12 immunotherapeutic – has been shown to increase survival in patients with recurrent glioblastoma. The results come from a Phase I clinical trial sponsored by Ziopharm Oncology Inc. (MA, USA). The clinical trial from researchers at the Brigham and Women’s Hospital and the Dana-Farber Cancer Institute (both MA, USA) has tested the efficacy of an oral therapy that controls an immunotherapeutic, known as human interleukin-12 (IL-12). Previous clinical trials for IL-12 have been halted due to concerns over toxicity; however, the new drug (veledimex) has shown that it’s use is viable in...

To view the full article, please register now for access

It's completely free